НАНОМЕДИЦИНА У ПРОТИПУХЛИННІЙ ТЕРАПІЇ
DOI:
https://doi.org/10.20998/2079-0821.2022.01Ключові слова:
ліпосомальні препарати, протипухлинні препарати, антиоксиданти, антирациклінові антибіотики, доцетаксел, препарати платини, іринотекан, кверцетин, куркумінАнотація
Використання ліпосомальних наночастинок як drug delivery system сьогодні є перспективним напрямком сучасної нанофармакології, зокрема у розробці протипухлинних лікарських препаратів. Ліпосомальні форми протипухлинних активних фармацевтичних інгредієнтів характеризуються зниженням токсичності, забезпеченням стабільності та підвищенням протипухлинної активності інкапсульваного у наночастинки протипухлинного агенту, пролонгованістю дії препарату. Представлені на ринку ліпосомальні протипухлинні засоби є препаратами із пасивним націлюванням, які накопичуються у клітинах шляхом пасивної дифузії пухлини завдяки EPR-ефекту судинної системи. У даному огляді представлені дані вивчення протипухлинної активності ліпосомальних препаратів, проведених українськими вченими протягом останніх десятиліть. Сьогодні доведена протипухлинна активність ліпосомальних форм терапевтичних агентів різної природи: антрациклінові антибіотики, препарати платини, напівсинтетичні похідні алкалоїдів, природні поліфенольні антиоксиданти, тощо. Так, інкапсуляція доксорубіцину гідрохлориду у ліпосоми дозволило знизити його кардіотоксичність та інші побічні ефекти, забезпечити можливість лікування резистентних до доксорубіцину пухлин. Ліпосомальні форми комплексних сполук платини, зокрема цисплатину, у порівнянні із вільними формами цитостатиків показали більшу ефективність при лікуванні резистентного до цисплатину раку яєчників. Застосування поліфенольних антиоксидантів, кверцетину та куркумін, у комплексній терапії дозволяє не лише посилити протипухлинний ефект, але й виявляю протективний ефект на здорові тканини та органи.
Посилання
Rommasi F., Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Research Letters. 2021, vol. 16, no. 1. pp. 95-104.
Shvets V.I., Krasnopolsky Yu.M., Sorokoumova G.M. Lipo¬somal forms of drugs: technological features of production and use in the clinic. Moscow: Remedium, 2016. 200 p.
Khromov A.S. Liposomal drugs - implementation of nanotechnology in medicine. Pharmacology and drug toxicology. 2016, vol. 2, no. 48. pp. 14-23.
Krasnopolskii Yu.M., Grigor’eva A.S., Katsai A.G. et al. Technologies and perspectives of liposomal drug applica¬tion in clinical practice. Nanotechnology in Russsia. 2017, vol. 12, no. 7–8. pp. 461-470.
Bubake U., Doppalapudi S., Kommineni N., Khan W. Lipo¬somal formulation in clinical use: an uphated review. Pharmaceutics. 2017. V.9, no. 2. pp. 12-26.
Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical application. Advanced Drug Delivery Reviews. 2013, vol. 65, no. 1. pp. 36-48.
Anchordoquy T.I., Barenholz Y., Boraschi D. et al. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano. 2017, vol. 11, no. 1. pp. 12-18.
Stadnichenko A.V.,Dudnichenko A.S.,Krasnopolsky Yu.M. Liposomal anticancer drugs. Kharkiv:"Madrid", 2018. 256р.
Golombek S.K., May J.N., Theek B., et al. Tumor targeting via EPR: strategies to enhance patient responses. Advanced Drug Delivery Reviews. 2018, vol. 130. pp. 17-38.
Danhier F.J. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? Journal of Control Release. 2016, vol. 244. pp. 108-121.
Olusanya T.O.B., Ahmad R.R.H., Ibegbu D.M. et al. Liposomal drug delivery systems and anticancer drug. Molecules. 2018, vol. 23, no. 4. pp. 907-914.
Franco Y.L., Vaidya T.R., Ait-Oudhia S. Anticancer and cardioprotective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer. 2018, vol. 10, no. 2. pp. 131-141.
Dranov O.L., Dudnichenko A.S., Butenko K.A. et al. Lipo¬somal forms of cytostatics - a new direction in cancer che¬motherapy. News of pharmacy. 1994, vol. 3. pp. 88-92.
Dudnichenko A.S., Krasnopolsky Yu.M. Results of experi¬mental studies of liposomal forms of anthracyclines and 5-fluorouracil. Experimental oncology. 1996, vol. 18, no. 2. pp. 125-129.
Krasnopolsky Yu.M., Dranov A.L., Stepanov A.E., Shvets V.I. Liposomal forms of cytostatics in oncology. Bulletin of Russian Academy of Medical Sciences.1998, vol. 5. pp. 35-40.
Shalkov Yu.L., Dudnichenko A.S., Krasnopolsky Yu.M. Experience and prospects for the use of liposomal forms of anticancer drugs in clinical oncology. Clinical Surgery. 1995, vol. 5. pp. 21-23.
Dudnichenko O.S. Liposomal preparations and other modifiers for stage IV gastrointestinal cancer: Absrtact of Dr. med.sci. dis., Kyiv, 1996. 32 p.
Ponomareva O.V., Kindzelsky L.P., Kulik G.I. Liposomal form of doxorubicin hydrochloride "Lipodox" in the treatment of lymphogranulomatosis and non-Hodgkin's lymphomas. Medical Affair. 2001, vol. 1. pp. 112-117.
Ponomareva O.V., Kulik G.I., Bondaruk O.S. et al. Lipo¬so¬mal form of doxorubicin (Lipodox) in the treatment of pati¬ents with breast cancer. Oncology. 2004, vol. 6. pp. 211-214.
Дудниченко О.С., Бутенко К.А.,Краснопольський Ю.М., Теміров Ю.П. Pat. Ukraine No. 14629. Спосiб одержання лiпосомальної форми протипухлинного препарату. 1997.
Dudnichenko A.S., Temirov Y.P., Shvets V.I., Krasnopolskiy Y.M. Pat. Ukraine No. 64591. Method for obtaining liposomal form of antitumor antibiotic. 2006.
Kulik G.I., Ponomareva O.V., Korol V.I., Che-hun V.F. To¬xicity and anti-inflammatory activity of the liposomal dosa¬ge form of doxorubicin. Oncology. 2004. T. 6, no. 3. C. 207-210.
Anikusko M.F., Krasnopolsky Yu.M., Kulik G.I. et al. The use of liposomal forms for chemotherapy in patients with doxorubicin-resistant breast cancer. Oncology. 2007, vol. 9, no. 2. pp. 56-61.
Pivnyuk V.M., Timovska Y.O, Ponomareva O.V. et al. Use of liposomal forms of chemotherapeutics in patients with doxorubicin-resistant breast cancer. Oncology. 2007, vol. 9, no. 2. pp. 120-124.
Pivnyuk V.M., Ponomareva O.V., Yurchenko O.V. et al. Therapy of patients with malignant lymphomas using the liposomal form of doxorubicin: results of a 15-year follow-up. Oncology. 2013, vol. 15, no. 2. pp. 136-140.
Beletsky V.E., Dudnichenko A.S. Long-term results of treatment of solid tumors in children using free and liposomal doxorubicin. Problems of uninterrupted medical training and science. 2017, vol. 1. pp. 44-48.
Dudnichenko A.S., Goncharov V.I., Belozor N.V. et al. Modifying effect of liposomal doxorubicin on the effect of radiation therapy. Materials of the 5th Congress of Oncologists and Radiologists of the CIS. Tashkent, 2008. pp. 473-474.
Arantseva D.A., Vodovozova E.L. Anticancer drugs based on platinum and their liposomal forms in clinical trials. Bioorganic chemistry. 2018, vol. 44, no. 6. pp. 619-630.
Zahednezhad F., Zakeri-Milani P., Mojarrad J.S., Valizadeh H. The latest advances of Cisplatin liposomal formulations: essentials for preparation and analysis. Expert opinion on drug delivery. 2020, vol. 17, no. 4. pp. 523-541.
Liu V., Hu F., Zhao L. Effect of nano-platinum on proliferati and apoptosis of non-small cell lung cancer cells via P53 pathway. Journal of nanoscience and nanotech¬nology. 2021. V.21, no. 2. pp. 903-908.
Dudnichenko O.S., Temirov Y.P., Shvets V.I. et al.Pat. Ukraine No. 66633. Method for obtaining liposomal form of platinum antitumor drug. 2006.
Report on the creation and transfer of scientific and tech¬ni¬cal products entitled "Open study of the effectiveness and tolerability of the drug Lipoplat - lyophilized powder for preparation of solution for injection of 0.01 g in bottles of "Biolik" in comparison with Cisplatin, concentrate for infu¬sion 0.01 g in vials manufactured by “Mili Healthcare” in patients with ovarian cancer, primary and recurrence of sta¬ge III-IV, clinical group II". Kavetsky Institute of Experi¬mental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, 2007. 22 p.
Kulik G.I., Chekhun V.F., Todor I.N. Liposomal prepa¬ra¬tions: a way to overcome drug resistance to cisplatin. Onco¬logy. 2009, vol. 11, no. 1. pp. 76-80.
Xu B., Zeng M., Zang J. et al. Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposome cisplatin nonsmall cell lung cancer and squamous cell carcinoma of the head and neck. Medicina. 2018, vol. 97, no. 46. e13169.
Sarkar A. Novel platinum compounds and nanoparticles as anticancer agents. Pharmaceutical patent analyst. 2018, vol. 7, no. 1. pp. 33-46.
Yang C., Liu H., Fu Z.X. PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer via Fas/Fasl and caspase-8. Cell biology international. 2012, vol. 36, no. 3. pp. 289-296.
Li Z., Hai Ying M. Preparation of oxaliplatin long circulating liposomes and their pharmacodynamics in mice. Pharmaceutical Care and Research. 2015, vol. 15, no. 1. pp. 27-30.
Shi M., Fortin D., Paquette B., Sanche L. Convection – en¬hancement delivery of Liposomal formulation of oxali¬pla¬tin show less toxicity than oxaliplatin eyet maintains a similar medion servival time in E98 glioma-bearing rat model. Investigational new drugs. 2018, vol. 34, no. 3. pp. 269-276.
Stadnichenko O.V., Krasnopolsky Yu.M., Yarnikh T.G. Technological parameters for the production of liposomes with oxaliplatin. Pharmaceutical Review. 2018, vol. 1. pp. 57-62.
Stadnichenko O.V., Krasnopolsky Yu. M., Yarnykh T.G. et al. The Concept “Quality by Design” in development of li¬posomal cytostatics. Research Journal of Pharmacy and Technology. 2020. V.13, no. 2. pp. 674 – 678.
Стадниченко О.В., Краснопольський Ю.М., Ярних Т.Г. Pat. Ukraine No. 113456. Спосіб отримання ліпосома¬ль¬ного лікарського засобу з оксалиплатином. 2017.
Shobolov D.L., Krasnopolsky Yu.M., Ulyanov A.M. et al. Eurasian patent No. 023757. Method for obtaining the liposomal form of oxaliplatin. 2016.
Krasnopolsky Yu.M., Dudnichenko A.S., Shvets V.I. Phar¬maceutical biotechnology: Bionanotechnology in pharmacy and medicine. Kharkiv: NTU "KhPI", 2011. pp. 97-102.
Krasnopolsky Y.M., Dudnichenko А.S. Experimental study of liposomal docetaxel incorporation and stability. Experi¬mental Oncology. 2017, vol. 39, no. 2. pp. 121-123.
Shobolov D.L., Krasnopolsky Yu.M., Ulyanov A.M. et al. Eurasian patent No. 022182. Method for obtaining the liposomal form of docetaxel. 2015.
Sedova S.V., Avdeev O.I., Balabanyan V.Yu. et al. Comparative experimental toxicological study of cytostatics from the group of taxanes and their nanoscale dosage forms. Russian biotherapeutical journal. 2013, vol. 4. pp. 33-37.
Stadnichenko A.V., Krasnopolsky Yu.M., Shvets V.I., Yar¬nykh T.G. Study of the stability of irinotecan using various methods of active loading of liposomes. Scientific Journal ScienceRise: Pharmaceutical Science. 2016, vol. 2(2). pp. 30-35.
Stadnichenko O.V., Krasnopolsky Y.M., Yarnykh T.G. Study of optimal extrusion parameters in creation liposome with irinotecan. Pharmaceutical Journal. 2016, vol. 2. С.77-82.
Stadnichenko A.V., Krasnopolsky Yu.M., Shvets V.I., Yarnykh T.G. Determination of the internal volume of liposomes with irinotecan. Ukrainian Biopharmaceutical Journal. 2016, vol. 46, no. 5. pp. 64-67.
Stadnichenko OV, Krasnopolsky YM, Yarnykh TG Study of the composition of the lipid membrane in the creation of liposomes with irinotecan. Pharmaceutical Review. 2017, vol. 1. pp. 22-26.
Stadnichenko O.V., Krasnopolsky Yu. M., Yarnykh T.G. The study of liophilization parameters in the liposomal iri¬notecan development. Visnik Farmacii. 2017, vol. 92, no. 4. pp. 45-49.
Shobolov D.L., Krasnopolsky Yu.M., Ulyanov A.M. et al. Eurasian patent No. 023179. Method for obtaining the liposomal form of irinotecan. 2016.
Huc I., Brovkovych V., Nanobash Vili J. et al. Bioflavo¬noi¬des quercetin scavenges superoxide and increases nitric oxi¬de concentration in ischemic-reperfusion injury: an experi¬mental study. The British journal of surgery. 1998, vol. 85, no. 8. pp. 1080-1085.
Moibenko A.A., Maxyutina N.P., Parchomtnko A.N. Lipo¬xygenase and NO-synthase activities following acute myo¬cardial infarction, new aspects of treatment. III International congress of pathophysiology. Lahti, Finland,1998. pp. 9-10.
Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. European heart journal. 1997, vol. 18, no. 11. pp. 1231-1248.
Li X., Zhou N., Wang J. et al. Quercetin suppresses breast cancer stem cells (CL44+/CD24-) by inhobiting the P13K/Akt/mNOR-signaling pathway. Life Sciences. 2018, vol. 196, no. 1. pp. 56-62.
Baby B., Antony P., Vijayan R. Interactions of quercetin with receptor tyrosine Kinases associated with human lung carcinoma. Natural product research. 2018, vol. 34, no. 24. pp. 2928-2931.
Zverev Ya.F. Antitumor activity of flavonoids. Bulletin of Siberian Medicine. 2019, vol. 18, no. 2. pp. 181-194.
Vafadar A., Shabaninejad Z., Movahedpour A. et al. Quer¬cetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell and Bioscience. 2020, vol. 10, 32.
Hashemzaei M., Far A.D., Yari A. et al. Anticancer and apoptosis inducing effects of quercetin in vitro and in vivo. Oncology Report. 2017, vol. 38, no. 2. pp. 819-828.
Liu Y., Gong W., Yang Z. et al. Quercetin induces protective autophagy and apoptosis through ER-stress via the p-STAT3/Dcl-2 axis in ovarian cancer. Apoptosis. 2017, vol. 22, no. 4. pp. 544-547.
Yang Y., Wang T., Chen D. et al. Quercetin preferentially induces apoptosis in KRAS-mutant colorectal cancer cell via JNK signaling pathways. Cell biology international. 2019, vol. 43, no. 2. pp. 117-124.
Gong C., Yang Z., Zhang L. et al. Quercetin suppresses DNA-double-strand break repair and enhances the radio¬sensitivity of human ovarian cancer cells via p53 dependent endoplasmic reticulum stress pathway. OncoTargets and therapy. 2018, vol. 11. pp. 17-27.
Hemati M., Haghiralsadat F., Vazdian F. et al. Development and characterization of a novel cationic PEGylated noisome-encapsulated forms of doxorubicin, quercetin siRNA for the treatment of cancer dy using combination therapy. Artificial cells, nanomedicine, and biotechnology. 2019, vol. 47, no. 1. pp. 1295-1311.
Stefanov O.V., Grigorieva G.S., Soloviev O.I. et al. Pat. Ukraine No. 76393. The method of obtaining liposomal agent containing quercetin. 2006.
Grigorieva G.S., Krasnopolsky Yu.M., Konakhovich N.F., Pasechnikova N.V. Pat. Ukraine No. 111762. A method of obtaining a pharmacologically active liposomal agent containing quercetin. 2016.
Belik G.V., Grigorieva G.S., Gorban E.M., Derimedvid L.V. Peculiarities of the action of the liposomal form of quercetin on the model of doxorubicin cardiomyopathy. Medicines. 2004, vol. 5-6. pp. 60-63.
El Aaraj Ahmad, Zupanets I.A., Shebeko S.K., Otrishko I.A. The effect of the combination of quercetin with a gluco-substitute derivative on the course of doxorubicin cardio¬myo¬pathy in rats. Clinical pharmacy. 2012, vol. 16, no. 3. pp. 24-27.
Belik G.V., Drovovoz S.M., Grigorieva G.S. Pat. Ukraine No. 79900. Method of correcting cardiotoxic action of doxo¬rubicin by quercetin. 2007.
Хавич О.А. Expansion of indicators for the use of liposomal agents in tumor growth. Pharmacology and drug toxicology. 2016, vol. 3(49). pp. 99-103.
Antipova S.V., Shepilov O.D., Ryabtseva O.D. Experience of using Lipoflavone to prevent the development of cardiac complications in patients with operable breast cancer treated with anthracyclines. Problems of modern medicine, science and education. 2009, vol. 2. pp. 44-46.
Shchetinina T.A., Shepil A.V. Evaluation of the effe¬ctiveness of the use of Lipoflavone to prevent the develop¬ment of cardiac complications in patients with operable breast cancer receiving anthracycline treatment. Ukrainian Medical Almanac. 2008, vol. 11, no. 5. pp. 207-208.
Uzlenkova N.E., Grigorieva G.S., Konakhovich N.F. et al. Experimental evaluation of the effectiveness of liposomal preparation for the prevention of mitigation of radiation complications. Proceedings of the scientific-practical confe¬rence of the Society of Radiation Oncologists. Ukrainian Radiological Journal (Appendix). Poltava, 2019. pp. 57-58.
Feng T., Wei Y., Lee R.J., et al. Liposomal curcumin and its application in cancer. International journal of nano¬medicine. 2017. V.12. pp. 6027-6044.
Pylypenko D.M., Gorbach T.V., Katsai O.G. et al. A study of oxidative stress markers when using the liposomal anti¬oxidant complex. Pharmakeftiki. 2019, vol. 31, no. 1. pp. 40-47.
Pylypenko D., Gorbach T. Krasnopolsky Yu. Study of antioxidant activity of liposomal forms of quercetin and curcumin ischemic heart disease. BioTechnologia. 2020, vol. 101, no. 4. pp. 273-282.
Grigorieva G.S., Krasnopolsky Yu.M. Liposomes per se pharmacotherapeutic status. Pharmacology and drug toxi¬cology.2020, vol. 14, no. 4. pp. 264-271.
Allen T. Ligant-targeted therapeutics in anticancer therapy. Nature Reviews Cancer. 2002, vol. 2, no. 10. pp. 750-763.
Liechty W.B., Peppas N.A. Expert opinion: responsive poly¬mer nanoparticles in cancer therapy. European journal of pharmaceutics and biopharmaceutics. 2012, vol. 80, no. 2. pp. 241-246.
Deshpande P.P., Biswas S., Torchilin V.P. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013, vol. 8, no. 9. pp. 1509-1528.
Alekseeva A.S. Mechanisms of interaction with cells of antitumor liposomes with lipophilic prodrugs: candidate of chem. sci. dis. Moscow, 2018. 105 p.
Ke P.C., Lin S., Parak W.L. et al. A decade of the protein corona. ACS Nano. 2017, vol. 11, no. 12. pp. 11773-11776.
Fleishher B., Lezeau S., Werkman C. et al. In vitro to clinical translation of combinatorial, effects of doxorubicin and abemaciclib in rb-positive triple negative breast cancer: a system-based pharmacokinetic pharmacodynamic mode¬ling approach. Breast Cancer. 2021, vol. 19. pp. 87-105.
Zheng J., Pan Y., Shi Q. et al. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. Cancer Communications. 2022, vol. 42, no. 1. pp. 3-6.
Zawilska P., Machowska M., Wisniewski K. et al. Novel pegylated liposomal formulation of docetaxel with 3-n-pen¬tadecylphenol derivate for cancertherapy. European Journal of Pharmaceutical Sciences. 2021, vol. 163. 105838.
